THX Pharma

As of December 31, 2024, THX Pharma carries a market capitalization of 4.51M, placing it among publicly traded companies globally. Its enterprise value stands at 6.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, THX Pharma has 8.51M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, THX Pharma maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, THX Pharma's stock has gained approximately 34.05% over the past 52 weeks. The 50-day moving average sits at 3.57, while the 200-day moving average is 3.35.

As of December 31, 2024, THX Pharma holds 966,589.00 in cash and equivalents against 2.87M in total debt, resulting in a net debt position of 2.16M. Total book value stands at -1.66M, with working capital of -6,151.00 providing operational flexibility.

THX Pharma's most recent stock split took place on October 27, 2025 with a 749:779 split ratio.